Clinical Trial Update: Effect of Linagliptin on Vascular Inflammation in Patients With Type 2 Diabetes Mellitus [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating linagliptin for vascular inflammation in patients with type 2 diabetes mellitus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Tradjenta (Linagliptin)

Snippet

Sponsor: RWTH Aachen University | Conditions: Diabetes Mellitus Type 2 (T2DM), Vascular Inflammation | Phase 3 | Status: TERMINATED